S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,533.58 +0.99%
Next Bullish Trade
Sign in
NVS

NVS NVS

$153.76 +1.03 (+0.67%)
Neutral · +0.20σ
+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · NVS

Momentum reads · latest daily bar
Last
$153.76
+1.03 (+0.67%)
Mkt cap
$293.4B
Healthcare
RSI(14)
51.9
neutral
Stochastic %K
25.5
neutral
MFI(14)
41.6
neutral
ADX(14)
11.3
weak trend

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $13.5B $3.2B $4.2B $2.9B 23.3% 31.3%
2025-12-31 $13.9B $2.4B $3.6B $1.2B 17.4% 26.1%
2025-09-30 $14.4B $3.9B $4.5B $5.7B 27.4% 31.3%
2025-06-30 $14.8B $4.0B $4.9B $6.1B 27.2% 32.8%
2025-03-31 $13.6B $3.6B $4.7B $2.2B 26.5% 34.2%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare NVS vs peers

Line NVS up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing NVS no peers yet — add up to 4 below
Sector peers + LLY + UNH + JNJ + MRK + ABBV + PFE
Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Add tickers to compare with NVS

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 20 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2026-04-27 1.65 1.65 +0.0% +0.9%
2026-02-04 2.03 2.00 +1.3% +0.7%
2025-10-28 2.25 2.31 -2.6% -1.3%
2025-07-17 2.42 2.37 +2.0% -0.2%
2025-04-29 2.28 2.17 +5.0% +0.0%
2025-01-30 1.98 1.76 +12.7% -0.0%
2024-10-28 2.06 1.93 +6.6% -4.4%
2024-07-17 1.97 1.86 +5.9% -4.1%
2024-04-22 1.80 1.68 +6.9% +2.3%
2024-01-30 1.53 1.66 -7.7% -4.0%
2023-10-24 1.74 1.74 -0.2% +0.6%
2023-07-17 1.83 1.76 +4.0% +4.6%
2023-04-25 1.71 1.53 +11.9% -1.4%
2023-01-31 1.52 1.43 +6.0% -2.6%
2022-10-25 1.58 1.62 -2.2% +1.4%
2022-07-19 1.56 1.54 +1.4% -2.1%
2022-04-26 1.46 1.51 -3.2% +0.5%
2022-02-02 1.40 1.41 -1.0% +0.6%
2021-10-26 1.71 1.66 +3.2% -2.5%
2021-07-21 1.66 1.49 +11.7% +0.7%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
NVS ★ $293B 22.0 15.8 5.2 14.6 7.6 75.6% -0.7% -9.3% 4.10%
LLY $1,051B 41.8 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 32.1 19.2 0.9 17.7 4.0 19.5% 0.4% 61.5% 5.88%
JNJ $609B 29.3 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0% —
MRK $315B 36.0 13.2 4.8 12.1 6.9 76.7% 4.9% — 4.46%
ABBV $450B 124.8 15.6 7.2 17.2 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.6 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.2 19.5 4.4 21.1 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 3.35%

HolderShares% out
Fisher Asset Management, LLC 13,885,749 0.68%
Morgan Stanley 8,527,037 0.42%
Dimensional Fund Advisors LP 8,110,116 0.40%
Primecap Management Company 7,567,354 0.37%
Dodge & Cox Inc. 6,967,383 0.34%
Goldman Sachs Group Inc 6,525,771 0.32%
LOOMIS SAYLES & CO L P 5,426,100 0.27%
Bank of America Corporation 4,962,794 0.24%
Franklin Resources, Inc. 3,409,944 0.17%
Blackrock Inc. 2,949,760 0.14%

Insider activity · 90d

No insider trades for NVS in last 90d.

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$123.0
Mean
$154.565
High
$180.0
Analysts
10
Recommendation distribution · period 2026-07-01
6
11
14
3
Revision trend (2026-04-01 → 2026-07-01): net 12 → 14 +2 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
4 2020-07-16 4 view ·
4 2020-07-02 4 view ·
4 2020-06-22 PRIMARY DOCUMENT view ·
4 2020-06-17 PRIMARY DOCUMENT view ·
4 2020-06-12 PRIMARY DOCUMENT view ·
4 2020-06-09 PRIMARY DOCUMENT view ·
4 2020-06-04 PRIMARY DOCUMENT view ·
4 2019-11-12 FORM 4 SUBMISSION view ·
4 2019-05-30 4 view ·
4 2019-04-29 PRIMARY DOCUMENT view ·
4 2019-04-24 PRIMARY DOCUMENT view ·
4 2019-04-15 PRIMARY DOCUMENT view ·
4 2019-04-10 PRIMARY DOCUMENT view ·
4 2019-04-05 PRIMARY DOCUMENT view ·
4 2019-04-02 PRIMARY DOCUMENT view ·
4 2019-04-02 PRIMARY DOCUMENT view ·
4 2019-03-28 PRIMARY DOCUMENT view ·
4 2019-03-15 PRIMARY DOCUMENT view ·
4 2018-10-04 PRIMARY DOCUMENT view ·
4 2018-09-14 PRIMARY DOCUMENT view ·
4 2018-08-22 PRIMARY DOCUMENT view ·
4 2018-08-22 PRIMARY DOCUMENT view ·
4 2018-08-20 PRIMARY DOCUMENT view ·
4 2018-08-16 PRIMARY DOCUMENT view ·
4 2018-08-14 PRIMARY DOCUMENT view ·
4 2018-08-10 PRIMARY DOCUMENT view ·
4 2018-08-08 PRIMARY DOCUMENT view ·
4 2018-08-06 PRIMARY DOCUMENT view ·
4 2018-08-02 PRIMARY DOCUMENT view ·
4 2018-07-31 PRIMARY DOCUMENT view ·
4 2018-07-27 PRIMARY DOCUMENT view ·
4 2018-07-25 PRIMARY DOCUMENT view ·
4 2018-07-18 PRIMARY DOCUMENT view ·
4 2018-07-13 PRIMARY DOCUMENT view ·
4 2018-06-19 PRIMARY DOCUMENT view ·
4 2018-06-15 PRIMARY DOCUMENT view ·
4 2018-05-17 PRIMARY DOCUMENT view ·
4 2018-05-14 FORM 4 view ·
4 2018-05-11 FORM 4 view ·
4 2018-05-09 FORM 4 view ·
4 2018-04-23 4 view ·
4 2018-04-18 PRIMARY DOCUMENT view ·
4 2018-04-04 FORM 4 SUBMISSION view ·
4 2018-03-19 PRIMARY DOCUMENT view ·
4 2018-02-15 PRIMARY DOCUMENT view ·
4 2018-01-19 PRIMARY DOCUMENT view ·
4 2017-12-15 PRIMARY DOCUMENT view ·
4 2017-12-14 4 view ·
4 2017-11-16 PRIMARY DOCUMENT view ·
4 2017-08-23 PRIMARY DOCUMENT view ·
4 2017-07-05 FORM 4 SUBMISSION view ·
4 2017-06-20 FORM 4 SUBMISSION view ·
4 2017-06-12 FORM 4 SUBMISSION view ·
4 2017-06-08 FORM 4 SUBMISSION view ·
4 2017-06-06 FORM 4 SUBMISSION view ·
4 2017-06-02 FORM 4 SUBMISSION view ·
4 2017-05-30 FORM 4 SUBMISSION view ·
4 2017-05-25 FORM 4 SUBMISSION view ·
4 2017-05-22 FORM 4 SUBMISSION view ·
4 2017-05-18 FORM 4 SUBMISSION view ·

About NVS

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespeci…

Options picks · NVS

ITM + OTM ideas from the latest scan

Loading…

Congress trades · NVS

STOCK Act disclosures

Loading…

SEC filings & insiders · NVS

EDGAR · live

Loading…

Holders · NVS

Institutions & insider activity

Loading…